Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.22.38 - cathepsin K

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acro-Osteolysis
Current research on pycnodysostosis.
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.
Adenocarcinoma
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
[Diagnostic value of biomarkers of bone metabolism in the gingival fluid in inflammatory-destructive and tumor oral pathology].
Adenocarcinoma of Lung
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
Adenocarcinoma, Bronchiolo-Alveolar
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
Adenoma, Oxyphilic
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Alveolar Bone Loss
Adipokine Chemerin Bridges Metabolic Dyslipidemia and Alveolar Bone Loss in Mice.
Analysis of Cathepsin-K Activity at Tooth and Dental Implant Sites and the Potential of This Enzyme in Reflecting Alveolar Bone Loss.
Effects of Probiotic Culture Supernatant on Cariogenic Biofilm Formation and RANKL-Induced Osteoclastogenesis in RAW 264.7 Macrophages.
Alveolitis, Extrinsic Allergic
Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis.
Amyloidosis
A putative role for cathepsin K in degradation of AA and AL amyloidosis.
Aneurysm
Cathepsin K gene disruption does not affect murine aneurysm formation.
Differences in Elastin and Elastolytic Enzymes between Men and Women with Abdominal Aortic Aneurysm.
Osteoclast-Like Cells in Aneurysmal Disease Exhibit an Enhanced Proteolytic Phenotype.
Angina, Stable
Decreased Cathepsin K Plasma Level may Reflect an Association of Osteopoenia/Osteoporosis with Coronary Atherosclerosis and Coronary Artery Calcification in Male Patients with Stable Angina.
Angiomyolipoma
Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.
Premelanosome-negative inflammatory angiomyolipoma of liver with expression of cathepsin K and TFE3.
t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
Aortic Aneurysm, Abdominal
Assessing the targeting and fate of cathepsin k antibody-modified nanoparticles in a rat abdominal aortic aneurysm model.
Cathepsin K Deficiency Reduces Elastase Perfusion-Induced Abdominal Aortic Aneurysms in Mice.
Arthralgia
Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis.
Arthritis
Analysis of the kinetics of osteoclastogenesis in arthritic rats.
Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Cathepsin K Inhibitor Regulates Inflammation and Bone Destruction in Experimentally Induced Rat Periapical Lesions.
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin K Is Involved in Development of Psoriasis-like Skin Lesions through TLR-Dependent Th17 Activation.
Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
Cathepsin K: a unique collagenolytic cysteine peptidase.
Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
Detection of femtomole quantities of mature cathepsin K with zymography.
Effect of a cathepsin K inhibitor on arthritis and bone mineral density in ovariectomized rats with collagen-induced arthritis.
Effect of M3 muscarinic acetylcholine receptor deficiency on collagen antibody-induced arthritis.
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Inhibition of cathepsin K alleviates autophagy-related inflammation in periodontitis-aggravating arthritis.
Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10.
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
Role of cathepsin K in normal joints and in the development of arthritis.
Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice.
The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice.
Arthritis, Experimental
An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collagen-induced arthritis.
Effect of a cathepsin K inhibitor on arthritis and bone mineral density in ovariectomized rats with collagen-induced arthritis.
Effects of the Cathepsin K Inhibitor ONO-5334 and Concomitant Use of ONO-5334 with Methotrexate on Collagen-Induced Arthritis in Cynomolgus Monkeys.
Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
Joint Degradation in a Monkey Model of Collagen-Induced Arthritis: Role of Cathepsin K Based on Biochemical Markers and Histological Evaluation.
Myricetin ameliorates the symptoms of collagen-induced arthritis in mice by inhibiting cathepsin K activity.
Arthritis, Psoriatic
Effect of Vitamin D on Peripheral Blood Mononuclear Cells from Patients with Psoriasis Vulgaris and Psoriatic Arthritis.
Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Arthritis, Rheumatoid
An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collagen-induced arthritis.
Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium.
Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction.
Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role.
Effect of a cathepsin K inhibitor on arthritis and bone mineral density in ovariectomized rats with collagen-induced arthritis.
Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Myricetin ameliorates the symptoms of collagen-induced arthritis in mice by inhibiting cathepsin K activity.
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.
The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis.
The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Atherosclerosis
18F-FDG PET/MR-imaging in a Göttingen Minipig model of atherosclerosis: Correlations with histology and quantitative gene expression.
Cathepsin cysteine proteases in cardiovascular disease.
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin K: a unique collagenolytic cysteine peptidase.
Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients.
Detection of femtomole quantities of mature cathepsin K with zymography.
Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation.
Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis.
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Gene profiling of cathepsin K deficiency in atherogenesis: profibrotic but lipogenic.
Human macrophage foam cells degrade atherosclerotic plaques though cathepsin K mediated processes.
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor.
Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice.
Autoimmune Diseases
Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
Axial Spondyloarthritis
Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals.
Bone Diseases
Cathepsin K: a therapeutic target for bone diseases.
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Evaluation of Dexamethasone-Induced Osteoporosis In Vivo Using Zebrafish Scales.
Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An In Silico and In Vitro Study.
Lessons from rare diseases of cartilage and bone.
New therapeutic agents for the treatment of bone diseases.
Osteopetrosis and osteoporosis: two sides of the same coin.
Bone Diseases, Metabolic
Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K.
Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density.
Osteopenia due to enhanced cathepsin K release by BK channel ablation in osteoclasts.
Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
Serum Cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
The development and characterization of an ELISA specifically detecting the active form of cathepsin K.
Bone Resorption
(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.
(-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
A cytochemical assay for osteoclast cathepsin K activity.
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis.
A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor.
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Abnormal bone architecture in mice expressing MyD88 in cells of the osteoclast lineage.
Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K.
Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis.
Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.
Actin-binding protein coronin 1A controls osteoclastic bone resorption by regulating lysosomal secretion of cathepsin K.
Activation of the PGC-1?/NFATc-1 Pathway in Circulating Osteoclast Precursors Associated with Bone Destruction in Rheumatoid Arthritis.
Adenosine A2A receptor activation prevents wear particle-induced osteolysis.
Advances in the discovery of cathepsin K inhibitors on bone resorption.
Aging and menopause reprogram osteoclast precursors for aggressive bone resorption.
Altered Hematopoietic Stem Cell and Osteoclast Precursor Frequency in Cathepsin K Null Mice.
Ampelopsis brevipedunculata extract prevents bone loss by inhibiting osteoclastogenesis in vitro and in vivo.
An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.
Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro.
Antibodies to Citrullinated Proteins (ACPA) Associate with Markers of Osteoclast Activation and Bone Destruction in the Bone Marrow of Patients with Rheumatoid Arthritis.
Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis.
Antiosteoporotic activity and constituents of Podocarpium podocarpum.
AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors.
AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells.
Associations of Serum Cathepsin K and Polymorphisms in CTSK Gene With Bone Mineral Density and Bone Metabolism Markers in Postmenopausal Chinese Women.
Augmented LPS responsiveness in type 1 diabetes-derived osteoclasts.
Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma.
Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.
AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats.
Beneficial effect of 2'-acetylacteoside on ovariectomized mice via modulating the function of bone resorption.
Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffolds: synthesis and cysteinyl proteinase inhibition.
Biosynthesis and processing of cathepsin K in cultured human osteoclasts.
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.
Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.
Boric acid inhibits alveolar bone loss in rat experimental periodontitis through diminished bone resorption and enhanced osteoblast formation.
Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption.
Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
cAMP-PKA signaling pathway regulates bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
Cannabinoid receptor 2 agonist prevents local and systemic inflammatory bone destruction in rheumatoid arthritis.
Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption.
Cathepsin K and the design of inhibitors of cathepsin K.
Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption.
Cathepsin K Controls Cortical Bone Formation by Degrading Periostin.
Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in
Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.
Cathepsin K in melanoma invasion.
Cathepsin K in treatment monitoring following intravenous zoledronic acid.
Cathepsin K inhibitor causes changes in crystallinity and crystal structure of newly-formed mandibular bone in rats.
Cathepsin K Inhibitor Regulates Inflammation and Bone Destruction in Experimentally Induced Rat Periapical Lesions.
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits.
Cathepsin K inhibitors: a novel target for osteoporosis therapy.
Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization.
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.
Cathepsin K-deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression.
Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
Cathepsin K: a therapeutic target for bone diseases.
Cathepsin K: isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene.
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Cathepsin K: The Action in and Beyond Bone.
Cathepsin K: The association between Cathepsin K expression and sphenoid sinus invasion of pituitary adenomas.
Cbl-PI3K interaction regulates Cathepsin K secretion in osteoclasts.
CD147 promotes the formation of functional osteoclasts through NFATc1 signalling.
Cementocytes Express Receptor Activator of the Nuclear Factor Kappa-B Ligand in Response to Endodontic Infection in Mice.
Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression.
Chemerin Treatment Inhibits the Growth and Bone Invasion of Breast Cancer Cells.
Cherubism mice also deficient in c-Fos exhibit inflammatory bone destruction executed by macrophages that express MMP14 despite the absence of TRAP+ osteoclasts.
Chloroquine ameliorates bone loss induced by d-galactose in male rats via inhibition of ERK associated osteoclastogenesis and antioxidant effect.
Chondroitin sulfate promotes activation of cathepsin K.
Chronic Psychosocial Stress Impairs Bone Homeostasis: A Study in the Social Isolation Reared Rat.
Clinical disorders of bone resorption.
Cloning and expression of rhesus monkey cathepsin K.
Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.
Comparison in localization between cystatin C and cathepsin K in osteoclasts and other cells in mouse tibia epiphysis by immunolight and immunoelectron microscopy.
Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts.
Craniosynostosis in pycnodysostosis: broadening the spectrum of the cranial flat bone abnormalities.
Cystatin B as an intracellular modulator of bone resorption.
Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction.
Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
Design of cathepsin k inhibitors for osteoporosis.
Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.
Diclofenac sodium inhibits NFkappaB transcription in osteoclasts.
Different cysteine proteinases involved in bone resorption and osteoclast formation.
Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K.
Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts.
Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis.
Disruption of the Man-6-P Targeting Pathway in Mice Impairs Osteoclast Secretory Lysosome Biogenesis.
Distinct roles of cathepsin K and cathepsin L in osteoclastic bone resorption.
Drynariae Rhizoma promotes osteoblast differentiation and mineralization in MC3T3-E1 cells through regulation of bone morphogenetic protein-2, alkaline phosphatase, type I collagen and collagenase-1.
Effect of cathepsin K inhibitors on bone resorption.
Effect of nonsurgical periodontal therapy on crevicular fluid levels of Cathepsin K in periodontitis.
Effect of novel N-cyano-tetrahydro-pyridazine compounds, a class of cathepsin K inhibitors, on the bone resorptive activity of mature osteoclasts.
Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-a double-blind, randomized, dose-finding study.
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies.
Effects and interaction of icariin, curculigoside, and berberine in er-xian decoction, a traditional chinese medicinal formula, on osteoclastic bone resorption.
Effects of 9cis,11trans and 10trans,12cis CLA on osteoclast formation and activity from human CD14+ monocytes.
Effects of angiotensin II type I receptor blocker losartan on orthodontic tooth movement.
Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture and Estimated Bone Strength.
Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
Emerging and potential therapies for osteoporosis.
Emerging pharmacologic therapies for osteoporosis.
Emerging Therapies for Osteoporosis.
Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Established and forthcoming drugs for the treatment of osteoporosis.
Evaluation of Dexamethasone-Induced Osteoporosis In Vivo Using Zebrafish Scales.
Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Expression and regulation of cathepsin K in skin fibroblasts.
Expression of bone resorption genes in osteoarthritis and in osteoporosis.
Expression of matrix-degrading cysteine proteinase cathepsin K in cholesteatoma.
Expression of the proteinase specialized in bone resorption, cathepsin K, in granulomatous inflammation.
Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells.
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Extract of Magnoliae Flos inhibits ovariectomy-induced osteoporosis by blocking osteoclastogenesis and reducing osteoclast-mediated bone resorption.
Female estrogen receptor beta-/- mice are partially protected against age-related trabecular bone loss.
Fisetin Inhibits Osteoclast Differentiation via Downregulation of p38 and c-Fos-NFATc1 Signaling Pathways.
Fluoride decreased osteoclastic bone resorption through the inhibition of NFATc1 gene expression.
Fumitremorgin C Attenuates Osteoclast Formation and Function via Suppressing RANKL-Induced Signaling Pathways.
Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.
Future directions for new medical entities in osteoporosis.
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Genomic organization and chromosome localization of the human cathepsin K gene (CTSK).
High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K.
High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy.
High glucose downregulates the effects of autophagy on osteoclastogenesis via the AMPK/mTOR/ULK1 pathway.
Histochemical examination of systemic administration of eldecalcitol combined with guided bone regeneration for bone defect restoration in rats.
Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.
HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro.
Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity.
Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.
Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme.
Human circulating monocytes can express receptor activator of nuclear factor-kappaB ligand and differentiate into functional osteoclasts without exogenous stimulation.
Human macrophage foam cells degrade atherosclerotic plaques though cathepsin K mediated processes.
Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
Identification of angiogenin as the osteoclastic bone resorption-inhibitory factor in bovine milk.
Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
IL-1alpha stimulates cathepsin K expression in osteoclasts via the tyrosine kinase-NF-kappaB pathway.
IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.
Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Impaired osteoclast homeostasis in the cystatin B-deficient mouse model of progressive myoclonus epilepsy.
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.
In situ hybridization for matrix metalloproteinase-1 and cathepsin K in rat root-resorbing tissue induced by tooth movement.
In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis.
Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss.
Increase in osteoclastogenesis in an obese Otsuka Long-Evans Tokushima fatty rat model.
Increased expression of the receptor for activation of NF-kappaB and decreased runt-related transcription factor 2 expression in bone of rats with streptozotocin-induced diabetes.
Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis-a paradoxical observation?
Inhibiting periapical lesions through AAV-RNAi silencing of cathepsin K.
Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid.
Inhibition of cathepsin k for treatment of osteoporosis.
Inhibition of cathepsin K--a novel approach to antiresorptive therapy.
Inhibition of Drynariae Rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides.
Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone.
Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An In Silico and In Vitro Study.
Inhibition of Ulmus davidiana Planch (Ulmaceae) on bone resorption mediated by processing of Cathepsin K in cultured mouse osteoclasts.
Inhibitors of cathepsin K: a patent review (2004 - 2010).
Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells.
Inhibitory Effects of 2N1HIA (2-(3-(2-Fluoro-4-Methoxyphenyl)-6-Oxo-1(6H)-Pyridazinyl)-N-1H-Indol-5-Ylacetamide) on Osteoclast Differentiation via Suppressing Cathepsin K Expression.
Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation.
Interleukin-1? promotes the LC3-mediated secretory function of osteoclast precursors by stimulating the Ca²?-dependent activation of ERK.
Interventional value of total flavonoids from Rhizoma Drynariae on Cathepsin K, a potential target of osteoporosis.
Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins.
Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling.
Isorhamnetin 3-O-neohesperidoside promotes the resorption of crown-covered bone during tooth eruption by osteoclastogenesis.
JiangTang XiaoKe granule attenuates cathepsin K expression and improves IGF-1 expression in the bone of high fat diet induced KK-Ay diabetic mice.
Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.
Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-?b and Nfatc1 Activities.
LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivo.
Lessons from rare diseases of cartilage and bone.
Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
Loss of Protein Kinase C-? Protects against LPS-Induced Osteolysis Owing to an Intrinsic Defect in Osteoclastic Bone Resorption.
Low bone turnover and reduced angiogenesis in streptozotocin-induced osteoporotic mice.
Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation.
Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction.
Low-intensity pulsed ultrasound protects subchondral bone in rabbit temporomandibular joint osteoarthritis by suppressing TGF-?1/Smad3 pathway.
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.
MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
Metabolic properties of the osteoclast.
Mineral trioxide aggregate inhibits osteoclastic bone resorption.
Molecular and cellular basis of bone resorption.
Molecular changes in Articular Cartilage and Subchondral Bone in the Rat Anterior Cruciate Ligament Transection and Meniscectomized Models of Osteoarthritis.
Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone.
Molecular mechanisms underlying osteoclast formation and activation.
Monocyte proliferation and differentiation to osteoclasts is affected by density of collagen covalently bound to a poly(dimethyl siloxane) culture surface.
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia.
Muramyl dipeptide enhances lipopolysaccharide-induced osteoclast formation and bone resorption through increased RANKL expression in stromal cells.
Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein.
N-Acetylcysteine Attenuates Lipopolysaccharide-Induced Osteolysis by Restoring Bone Remodeling Balance via Reduction of Reactive Oxygen Species Formation During Osteoclastogenesis.
Natural inhibitors targeting osteoclast-mediated bone resorption.
Neohesperidin suppresses osteoclast differentiation, bone resorption and ovariectomised-induced osteoporosis in mice.
New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand.
New insights into treatment of osteoporosis in postmenopausal women.
New targets for intervention in the treatment of postmenopausal osteoporosis.
New treatment targets in osteoporosis.
Nicotine affects bone resorption and suppresses the expression of cathepsin K, MMP-9 and vacuolar-type H(+)-ATPase d2 and actin organization in osteoclasts.
Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
Non-covalent cathepsin k inhibitors for the treatment of osteoporosis.
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption.
Novel biological markers of bone: from bone metabolism to bone physiology.
Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors.
Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice.
Odanacatib for the treatment of osteoporosis.
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect.
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density.
Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.
Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA.
Osseointegration and foreign body reaction: Titanium implants activate the immune system and suppress bone resorption during the first 4 weeks after implantation.
Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation.
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.
Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.
Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts.
Osteopenia due to enhanced cathepsin K release by BK channel ablation in osteoclasts.
Osteoprotegerin differentially regulates protease expression in osteoclast cultures.
Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA.
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors.
Peptidomimetic inhibitors of cathepsin K.
Pharmacokinetics and bone resorption evaluation of a novel Cathepsin K inhibitor (VEL-0230) in healthy adult horses.
Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
PKC? deficiency perturbs bone homeostasis by selective uncoupling of cathepsin K secretion and ruffled border formation in osteoclasts.
Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K.
Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.
Potential role of odanacatib in the treatment of osteoporosis.
PP121 suppresses RANKL-Induced osteoclast formation in vitro and LPS-Induced bone resorption in vivo.
Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Present and future pharmacotherapy for osteoporosis.
Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.
Prevalent and Emerging Therapies for Osteoporosis.
Preventive Effects of Chrysanthemum coronarium L. Extract on Bone Metabolism In Vitro and In Vivo.
Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.
Protective Effect of Acteoside on Ovariectomy-Induced Bone Loss in Mice.
Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope.
Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
Pycnodysostosis- a rare disorder with distinctive craniofacial dysmorphia. A case report.
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Quantification of the expression levels of lysosomal cysteine proteinases in purified human osteoclastic cells by competitive RT-PCR.
Radiation alters osteoclastogenesis by regulating the cytoskeleton and lytic enzymes in RAW 264.7 cells and mouse bone marrow-derived macrophages.
RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells.
RANKL and cathepsin K in diffuse sclerosing osteomyelitis of the mandible.
Regulation and enzymatic basis of bone resorption by human osteoclasts.
Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts.
Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
Regulatory properties of vitronectin and its glycosylation in collagen fibril formation and collagen-degrading enzyme cathepsin K activity.
Relation of Bone Mineral Density with Homocysteine and Cathepsin K levels in Postmenopausal Women.
Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
Repeated oral administration of a cathepsin K inhibitor significantly suppresses bone resorption in exercising horses with evidence of increased bone formation and maintained bone turnover.
Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Retinoic acid induces two osteocalcin isoforms and inhibits markers of osteoclast activity in Atlantic cod (Gadus morhua) ex vivo cultured craniofacial tissues.
Role of cathepsin K in normal joints and in the development of arthritis.
Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation.
Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis.
Role of odanacatib in reducing bone loss due to endodontic disease: An overview.
Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-?B and MAPK signaling pathway.
Serum and Urine Bone Resorption Markers and Pharmacokinetics of Cathepsin K Inhibitor ONO-5334 after Ascending Single Doses in Post-menopausal Women.
Serum Cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
Serum levels of cathepsin K decrease with age in both women and men.
Silencing of Ac45 Simultaneously Inhibits Osteoclast-Mediated Bone Resorption and Attenuates Dendritic Cell-Mediated Inflammation through Impairing Acidification and Cathepsin K Secretion.
Species differences between human and rat in the substrate specificity of cathepsin k.
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
Structure and chromosomal assignment of the human cathepsin K gene.
Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur.
Substance P modulates bone remodeling properties of murine osteoblasts and osteoclasts.
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Synthesis and evaluation of cis-hexahydropyrrolo[3,2-b]pyrrol-3-one peptidomimetic inhibitors of CAC1 cysteinyl proteinases.
The Actin-Binding Protein Cofilin and Its Interaction With Cortactin Are Required for Podosome Patterning in Osteoclasts and Bone Resorption In Vivo and In Vitro.
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
The collagenolytic activity of cathepsin K is unique among mammalian proteinases.
The crystal structure of human procathepsin K.
The development and characterization of an ELISA specifically detecting the active form of cathepsin K.
The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor.
The Future of Cysteine Cathepsins in Disease Management.
The future of osteoporosis treatment - a research update.
The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K.
The Inhibitory Effect of Alisol A 24-Acetate from Alisma canaliculatum on Osteoclastogenesis.
The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function.
The new partnership of genomics and chemistry for accelerated drug development.
The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro.
The regulation of bone resorption in tooth formation and eruption processes in mouse alveolar crest devoid of cathepsin k.
The regulation of cathepsin K gene expression.
The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
The role of cathepsin K in normal bone resorption.
The role of cathepsin K in oral and maxillofacial disorders.
Thickened skull, scoliosis and other skeletal findings in Unverricht-Lundborg disease link cystatin B function to bone metabolism.
Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.
Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.
Transmembrane protein 173 inhibits RANKL-induced osteoclast differentiation.
Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys.
Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
[Advances treatment of osteoporosis: new molecules, new strategies].
[Biological therapy for osteoporosis].
[Bone and bone related biochemical examinations. Bone and collagen related metabolites. Urinary and serum NTX as bone resorption markers]
[Bone remodeling: new therapeutic approaches]
[Cathepsin K and matrix metalloproteases activity in the bone tissue of OXYS rats with developing osteoporosis].
[New anti-osteoporotic drugs under development].
[Odanacatib (MK-0822)].
[Osteoporosis].
[Potential mechanism of transcription factor peroxisome proliferator-activated receptor-gamma coactivator-1 beta on promoting osteoclastogenesis].
[Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
[Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].
Bowen's Disease
Cathepsin K expression in basal cell carcinoma.
Breast Neoplasms
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.
Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models.
Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation.
Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer.
Cathepsin K regulates localization and secretion of Tartrate-Resistant Acid Phosphatase (TRAP) in TRAP-overexpressing MDA-MB-231 breast cancer cells.
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.
Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.
Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides.
Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells.
Obesity and Cathepsin K: A Complex Pathophysiological Relationship in Breast Cancer Metastases.
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Simvastatin and MBCD Inhibit Breast Cancer-Induced Osteoclast Activity by Targeting Osteoclastogenic Factors.
The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis.
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.
Bronchopulmonary Dysplasia
Cathepsin K deficiency aggravates lung injury in hyperoxia-exposed newborn mice.
Cathepsin K expression is diminished in infants with bronchopulmonary dysplasia.
Carcinogenesis
Proteins involved in cutaneous basal cell carcinoma development.
Carcinoma
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Basaloid squamous cell carcinoma of the maxillary sinus: Report of two cases in association with cathepsin K expression.
Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma.
Cathepsin K expression in basal cell carcinoma.
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization.
Cathepsin k is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro.
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
Cathepsin K modulates invasion, migration and adhesion of oral squamous cell carcinomas in vitro.
Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.
Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer.
Expression of cathepsins B, D and K in thymic epithelial tumours.
Identification of Cathepsin K in the Peritoneal Metastasis of Ovarian Carcinoma Using In-silico, Gene Expression Analysis.
Osteoclast-like giant cell rich carcinomas of the lung: a Clinicopathological, Immunohistochemical, and molecular study of three cases.
Photoactivated inhibition of cathepsin K in a 3D tumor model.
RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
Stromal expression of cathepsin K in squamous cell carcinoma.
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.
VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
Carcinoma, Basal Cell
Cathepsin K expression in basal cell carcinoma.
Carcinoma, Bronchogenic
Cathepsin K expression in human lung.
Carcinoma, Non-Small-Cell Lung
Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
The Potential Role of Cathepsin K in Non-Small Cell Lung Cancer.
Carcinoma, Ovarian Epithelial
Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer.
Carcinoma, Renal Cell
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.
Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
Carcinoma, Squamous Cell
Basaloid squamous cell carcinoma of the maxillary sinus: Report of two cases in association with cathepsin K expression.
Cathepsin K expression in basal cell carcinoma.
Cathepsin k is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro.
Expression of cathepsins B, D and K in thymic epithelial tumours.
Stromal expression of cathepsin K in squamous cell carcinoma.
The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.
Cardiomegaly
Cathepsin K knockout alleviates aging-induced cardiac dysfunction.
Cathepsin K Knockout Alleviates Pressure Overload-Induced Cardiac Hypertrophy.
Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction.
Cardiomyopathy, Dilated
Cathepsin K Knockout Alleviates Pressure Overload-Induced Cardiac Hypertrophy.
Cardiotoxicity
Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity.
Correction: Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity.
Cardiovascular Diseases
Cathepsin K - A classical bone biomarker in cardiovascular disease: The heart is not alone anymore.
Cathepsin K gene disruption does not affect murine aneurysm formation.
Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction.
Cathepsin K knockout protects against cardiac dysfunction in diabetic mice.
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Increased Circulating Cathepsin K in Patients with Chronic Heart Failure.
Mechanisms with clinical implications for atrial fibrillation-associated remodeling: cathepsin K expression, regulation, and therapeutic target and biomarker.
cathepsin k deficiency
A rare case of pycnodysostosis: Technical difficulties in managing long bone fractures.
Ablation of cathepsin k activity in the young mouse causes hypermineralization of long bone and growth plates.
Cathepsin K deficiency aggravates lung injury in hyperoxia-exposed newborn mice.
Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in
Cathepsin K Deficiency Impaired Ischemia-Induced Neovascularization in Aged Mice.
Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.
Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts.
Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Cathepsin K Deficiency Prevents the Aggravated Vascular Remodeling Response to Flow Cessation in ApoE-/- Mice.
Cathepsin K deficiency promotes alveolar bone regeneration by promoting jaw bone marrow mesenchymal stem cells proliferation and differentiation via glycolysis pathway.
Cathepsin K Deficiency Reduces Elastase Perfusion-Induced Abdominal Aortic Aneurysms in Mice.
Cathepsin K Deficiency Suppresses Disuse-Induced Bone Loss.
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
Cathepsin K: isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene.
Clinical and Radiographic Features of Pycnodysostosis with Emphasis on Dentofacial Problems.
Clinical disorders of bone resorption.
Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.
Disturbed remodeling and delayed fracture healing in pediatric pycnodysostosis patients.
Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon.
Function of Cathepsin K in the Central Nervous System of Male Mice is Independent of Its Role in the Thyroid Gland.
Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.
Gene profiling of cathepsin K deficiency in atherogenesis: profibrotic but lipogenic.
Immunology. The toll of cathepsin K deficiency.
Increased Bone Resorption during Lactation in Pycnodysostosis.
Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis.
Orthognathic surgery in pycnodysostosis: a case report.
Pedicle stress fracture: an unusual complication of pycnodysostosis.
PLF-1 (Proliferin-1) Modulates Smooth Muscle Cell Proliferation and Development of Experimental Intimal Hyperplasia.
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice.
The effect of cathepsin K deficiency on airway development and TGF-?1 degradation.
Thyroid functions of mouse cathepsins B, K, and L.
cathepsin s deficiency
Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice.
Cherubism
Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts.
Cholesteatoma
Expression of matrix-degrading cysteine proteinase cathepsin K in cholesteatoma.
Chondroma
Cysteine proteinases in chondrosarcomas.
Chondrosarcoma
Cysteine proteinases in chondrosarcomas.
Expression of cathepsin K in chordoma.
Chordoma
Expression of cathepsin K in chordoma.
Expression of cathepsin K in skull base chordoma.
Chronic Periodontitis
Comparative evaluation of cathepsin K levels in gingival crevicular fluid among smoking and nonsmoking patients with chronic periodontitis.
Colitis
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Colitis, Ulcerative
Laboratory control of the osteoresorptive effects of glucorcorticoids in patients with purpose colitis.
Colorectal Neoplasms
Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer.
Coronary Artery Disease
Circulating cathepsin K as a potential novel biomarker of coronary artery disease.
Decreased Cathepsin K Plasma Level may Reflect an Association of Osteopoenia/Osteoporosis with Coronary Atherosclerosis and Coronary Artery Calcification in Male Patients with Stable Angina.
Increased serum cathepsin K in patients with coronary artery disease.
COVID-19
Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases.
Craniopharyngioma
Cathepsin B, D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression.
Craniosynostoses
Pycnodysostosis with craniosynostosis: case report of the craniofacial and oral features.
Crohn Disease
Cathepsin-k as a diagnostic marker in the identification of micro-granulomas in Crohn's disease.
Cysts
Expression of the proteinase specialized in bone resorption, cathepsin K, in granulomatous inflammation.
Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
Dermatofibrosarcoma
Cathepsin K expression: a useful marker for the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Diabetes Mellitus, Type 1
Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats.
Diabetes Mellitus, Type 2
Histological evidence that metformin reverses the adverse effects of diabetes on orthodontic tooth movement in rats.
Dwarfism
Ablation of cathepsin k activity in the young mouse causes hypermineralization of long bone and growth plates.
Near Normalization of Adult Height and Body Proportions by Growth Hormone in Pycnodysostosis.
Echinococcosis
Expression of the proteinase specialized in bone resorption, cathepsin K, in granulomatous inflammation.
Encephalomyelitis
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Epilepsy
Micro-vibrations at 30?Hz on bone cells cultivated in vitro produce soluble factors for osteoclast inhibition and osteoblast activity.
Gaucher Disease
Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K.
Genetic Diseases, Inborn
Clinical and Radiographic Features of Pycnodysostosis with Emphasis on Dentofacial Problems.
Pycnodysostosis presenting as atypical stridor.
Pycnodysostosis with extreme sleep apnea: a possible alternative to tracheotomy.
Giant Cell Tumor of Bone
Cathepsin K is the principal protease in giant cell tumor of bone.
Cysteine proteinases in chondrosarcomas.
Giant Cell Tumors
Cathepsin K is the principal protease in giant cell tumor of bone.
Cysteine proteinases in chondrosarcomas.
Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry.
Glioblastoma
Cathepsin K cleavage of SDF-1? inhibits its chemotactic activity towards glioblastoma stem-like cells.
Correction: Expression Analysis of All Protease Genes Reveals Cathepsin K to Be Overexpressed in Glioblastoma.
Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma.
Localization patterns of cathepsins K and X and their predictive value in glioblastoma.
Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins.
Glioma
CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1?, CXCR4, Osteopontin and Cathepsin K.
Glucose Intolerance
Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction.
Glucose Metabolism Disorders
Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.
Granular Cell Tumor
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Granuloma
ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.
Cathepsin-k as a diagnostic marker in the identification of micro-granulomas in Crohn's disease.
Mycobacteria-induced granuloma necrosis depends on IRF-1.
Heart Diseases
Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity.
Inappropriate cathepsin K secretion promotes its enzymatic activation driving heart and valve malformation.
Heart Failure
Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity.
Increased Circulating Cathepsin K in Patients with Chronic Heart Failure.
Hematoma, Subdural, Chronic
Role of cathepsin K in the development of chronic subdural hematoma.
Histiocytoma, Benign Fibrous
Cathepsin K expression: a useful marker for the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
Cysteine proteinases in chondrosarcomas.
Dermatofibrosarcoma Protuberans: The Current State of Multidisciplinary Management.
Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation.
Hypercalcemia
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Hyperostosis
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.
Immune System Diseases
Emerging roles of cysteine cathepsins in disease and their potential as drug targets.
Immunoglobulin Light-chain Amyloidosis
A putative role for cathepsin K in degradation of AA and AL amyloidosis.
Infections
Fibroblast growth factor receptor 2 expression in apical periodontitis in mice.
HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro.
Immune response and expression analysis of cathepsin K in goldfish during Aeromonas hydrophila infection.
Inflammatory Bowel Diseases
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Keloid
Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation.
Keratoconus
Collagenolytic proteinases in keratoconus.
Keratosis, Actinic
Cathepsin K expression in basal cell carcinoma.
Kidney Neoplasms
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.
Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Leiomyoma
Coexistence of Conventional Leiomyoma, Fumarate Hydratase-deficient Atypical Leiomyoma, and Perivascular Epithelioid Cell Tumor in a Uterus: A Case Study.
Renal Leiomyoma: A Contemporary Multi-institution Study of an Infrequent and Frequently Misclassified Neoplasm.
Leukemia
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Lichen Planus, Oral
Cathepsin K expression is increased in oral lichen planus.
Lung Diseases
Cathepsin K overexpression modifies lung development in newborn mice.
Single-walled carbon nanotubes induce airway hyperreactivity and parenchymal injury in mice.
Lung Diseases, Interstitial
Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis.
Lung Injury
Cathepsin K deficiency aggravates lung injury in hyperoxia-exposed newborn mice.
Lung Neoplasms
Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer.
Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
The Potential Role of Cathepsin K in Non-Small Cell Lung Cancer.
Lymphangioleiomyomatosis
Cathepsin K in Lymphangioleiomyomatosis: LAM Cell-Fibroblast Interactions Enhance Protease Activity by Extracellular Acidification.
Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis.
Cathepsin-k expression in pulmonary lymphangioleiomyomatosis.
Lymphatic Metastasis
Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma.
Lysosomal Storage Diseases
Pycnodysostosis with unusual findings: a case report.
Melanoma
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Cathepsin K expression in basal cell carcinoma.
Cathepsin K expression in melanoma is associated with metastases.
Cathepsin K in melanoma invasion.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Memory Disorders
Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.
Characterisation and metabolism of astroglia-rich primary cultures from cathepsin K-deficient mice.
Function of Cathepsin K in the Central Nervous System of Male Mice is Independent of Its Role in the Thyroid Gland.
Metabolic Diseases
Excessive activity of cathepsin K is associated with cartilage defects in a zebrafish model of mucolipidosis II.
Microphthalmos
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family.
Odontoblast-like MDPC-23 cells function as odontoclasts with the RANKL/M-CSF induction.
The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor.
Mucolipidoses
Excessive activity of cathepsin K is associated with cartilage defects in a zebrafish model of mucolipidosis II.
Mucopolysaccharidoses
Glycosaminoglycan-Mediated Loss of Cathepsin K Collagenolytic Activity in MPS I Contributes to Osteoclast and Growth Plate Abnormalities.
Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.
Mucopolysaccharidosis VI
Alternative Method for Full Oral Rehabilitation in Patients with Pycnodysostosis Syndrome: ?A Case Report.
Mucositis
Estimation of Bone Loss Biomarkers as a Diagnostic Tool for Peri-Implantitis.
Multiple Myeloma
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Myocardial Infarction
Endogenous reduction of miR-185 accelerates cardiac function recovery in mice following myocardial infarction via targeting of cathepsin K.
Levels of cathepsins in acute myocardial infarction.
Neoplasm Metastasis
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.
Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.
Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma.
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Cathepsin K expression in melanoma is associated with metastases.
Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?
Cathepsin K inhibitors as treatment of bone metastasis.
Cathepsin K mRNA and protein expression in prostate cancer progression.
Cathepsin K: a unique collagenolytic cysteine peptidase.
Cathepsin K: The association between Cathepsin K expression and sphenoid sinus invasion of pituitary adenomas.
Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis.
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K.
Detection of femtomole quantities of mature cathepsin K with zymography.
Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer.
Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer.
Identification of Cathepsin K in the Peritoneal Metastasis of Ovarian Carcinoma Using In-silico, Gene Expression Analysis.
Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides.
Inhibitory effects of low intensity pulsed ultrasound on osteoclastogenesis induced in vitro by breast cancer cells.
Obesity and Cathepsin K: A Complex Pathophysiological Relationship in Breast Cancer Metastases.
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications.
Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis.
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.
The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
[Bony lesion with prostate cancer]
[Diagnostic value of biomarkers of bone metabolism in the gingival fluid in inflammatory-destructive and tumor oral pathology].
[Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy].
Neoplasms
A broad survey of cathepsin K immunoreactivity in human neoplasms.
A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.
A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
A soft coral-derived compound, 11-epi-sinulariolide acetate suppresses inflammatory response and bone destruction in adjuvant-induced arthritis.
ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.
Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer.
Ankle loading ameliorates bone loss from breast cancer-associated bone metastasis.
Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.
Azithromycin suppresses human osteoclast formation and activity in vitro.
Basaloid squamous cell carcinoma of the maxillary sinus: Report of two cases in association with cathepsin K expression.
Benign perivascular myoid cell tumor (myopericytoma) of the urinary tract: a report of 2 cases with an emphasis on differential diagnosis.
BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction.
Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.
C2K77 ELISA detects cleavage of type II collagen by cathepsin K in equine articular cartilage.
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas.
Cathepsin K expression in basal cell carcinoma.
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung.
Cathepsin K expression in melanoma is associated with metastases.
Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer.
Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization.
Cathepsin K inhibitors as treatment of bone metastasis.
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin k is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro.
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis.
Cathepsin K is the principal protease in giant cell tumor of bone.
Cathepsin K modulates invasion, migration and adhesion of oral squamous cell carcinomas in vitro.
Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors.
Cathepsin K: a unique collagenolytic cysteine peptidase.
Cathepsin K: The association between Cathepsin K expression and sphenoid sinus invasion of pituitary adenomas.
Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis.
CCR2 deficiency results in increased osteolysis in experimental periapical lesions in mice.
CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1?, CXCR4, Osteopontin and Cathepsin K.
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Coexistence of Conventional Leiomyoma, Fumarate Hydratase-deficient Atypical Leiomyoma, and Perivascular Epithelioid Cell Tumor in a Uterus: A Case Study.
Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.
Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium.
Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression.
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K.
Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
Cysteine cathepsins B, X and K expression in peri-arteriolar glioblastoma stem cell niches.
Cysteine proteinases in chondrosarcomas.
Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.
Daphnetin inhibits RANKL-induced osteoclastogenesis in vitro.
Detection of femtomole quantities of mature cathepsin K with zymography.
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Effects of 9cis,11trans and 10trans,12cis CLA on osteoclast formation and activity from human CD14+ monocytes.
Emerging therapeutic targets in breast cancer bone metastasis.
Estrogen-deficient osteoporosis enhances the recruitment and activity of osteoclasts by breast cancer cells.
Exosomal tumor necrosis factor-? from hepatocellular cancer cells (Huh-7) promote osteoclast differentiation.
Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Expression of cathepsin K in chordoma.
Expression of cathepsin K in neurofibromatosis 1-associated cutaneous malignant peripheral nerve sheath tumors and neurofibromas.
Expression of cathepsin K in skull base chordoma.
Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients.
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
FGF-8 is involved in bone metastasis of prostate cancer.
Fructus Ligustri Lucidi ethanol extract inhibits osteoclastogenesis in RAW264.7 cells via the RANKL signaling pathway.
Fructus Ligustri Lucidi preserves bone quality through the regulation of gut microbiota diversity, oxidative stress, TMAO and Sirt6 levels in aging mice.
Future directions of bone-targeted therapy for metastatic breast cancer.
Gene Expression in Osteolysis: Review on the Identification of Altered Molecular Pathways in Preclinical and Clinical Studies.
Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis.
Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer.
High fat diet-induced animal model of age-associated obesity and osteoporosis.
Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.
I?BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.
Increased osteoclast activity is associated with aggressiveness of osteosarcoma.
Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells.
Interactions between microenvironment and cancer cells in two animal models of bone metastasis.
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Interferon-? Released by Activated CD8(+) T Lymphocytes Impairs the Calcium Resorption Potential of Osteoclasts in Calcified Human Aortic Valves.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family.
Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation.
Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry.
Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts.
Macrophage cathepsin K promotes prostate tumor progression in bone.
Melanotic Xp11-associated tumor of the sigmoid colon: A case report.
MiR-377 inhibits wear particle-induced osteolysis via targeting RANKL.
Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Morphologic heterogeneity and markers of renal cell carcinoma with t(6; 11)(p21; q12): a case report and literature review.
Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.
New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption.
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
Ortho-silicic Acid Inhibits RANKL-Induced Osteoclastogenesis and Reverses Ovariectomy-Induced Bone Loss In Vivo.
Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation.
Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
Patterns and localization of gene expression during intramembranous bone regeneration in the rat femoral marrow ablation model.
PAX8 expression in sporadic hemangioblastoma of the kidney supports a primary renal cell lineage: implications for differential diagnosis.
PEComas of the kidney and of the genitourinary tract.
Photoactivated inhibition of cathepsin K in a 3D tumor model.
Premelanosome-negative inflammatory angiomyolipoma of liver with expression of cathepsin K and TFE3.
Primary cutaneous perivascular epithelioid cell tumor: a clinicopathological and molecular reappraisal.
Primary Giant Cell Tumors of the Lung: A Clinicopathologic and Immunohistochemical Study of 3 Cases.
Protocatechuic Acid Attenuates Trabecular Bone Loss in Ovariectomized Mice.
Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation.
Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.
Renal Cell Carcinomas With t(6;11)(p21;q12): A Clinicopathologic Study Emphasizing Unusual Morphology, Novel Alpha-TFEB Gene Fusion Point, Immunobiomarkers, and Ultrastructural Features, As Well As Detection of the Gene Fusion by Fluorescence In Situ Hybridization.
Review of renal carcinoma with t(6;11)(p21;q12-13) with focus on clinical and pathobiological aspects.
Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-?B pathways.
Stromal expression of cathepsin K in squamous cell carcinoma.
t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
The effects of mandibular osteotomy on maxillary orthodontic tooth movement and bone remodelling in a rat model.
The Influence of Bone Type on the Gene Expression in Normal Bone and at the Bone-Implant Interface: Experiments in Animal Model.
The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.
The Potential Role of Cathepsin K in Non-Small Cell Lung Cancer.
The role of cathepsin K in normal bone resorption.
Tumor Cell-Derived Exosomes from the Prostate Cancer Cell Line TRAMP-C1 Impair Osteoclast Formation and Differentiation.
Tumor necrosis factor alpha stimulates cathepsin K and V activity via juxtacrine monocyte-endothelial cell signaling and JNK activation.
Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors.
VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Xp11 translocation renal cell carcinoma.
Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
[Diagnostic value of biomarkers of bone metabolism in the gingival fluid in inflammatory-destructive and tumor oral pathology].
[Osteoimmunological aspects of periodontal inflammatory destructive changes at periimplantitis, chronic periodontitis and oncological diseases of the oral cavity].
[Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
Neuroblastoma
Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells.
Neurofibroma
Expression of cathepsin K in neurofibromatosis 1-associated cutaneous malignant peripheral nerve sheath tumors and neurofibromas.
Neurofibromatoses
Expression of cathepsin K in neurofibromatosis 1-associated cutaneous malignant peripheral nerve sheath tumors and neurofibromas.
Neurofibrosarcoma
Expression of cathepsin K in neurofibromatosis 1-associated cutaneous malignant peripheral nerve sheath tumors and neurofibromas.
Nevus
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Obesity
A single nucleotide polymorphism in the porcine cathepsin K (CTSK) gene is associated with back fat thickness and production traits in Italian Duroc pigs.
Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity.
Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin K: a unique collagenolytic cysteine peptidase.
Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients.
Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice.
Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice.
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Identification of cathepsin K as a novel marker of adiposity in white adipose tissue.
Obesity and Cathepsin K: A Complex Pathophysiological Relationship in Breast Cancer Metastases.
Optic Atrophy, Autosomal Dominant
Oxidative stress induced by fluoroquinolone enrofloxacin in zebrafish (Danio rerio) can be ameliorated after a prolonged exposure.
Osteitis Deformans
Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
Osteoarthritis
(1R,2R)-N-(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A Potent and Highly Selective Cathepsin K Inhibitor for the Treatment of Osteoarthritis.
Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis.
Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain.
Cathepsin cysteine proteases in cardiovascular disease.
Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis.
Cathepsin K Localizes to Equine Bone
Chicken collagen type II reduces articular cartilage destruction in a model of osteoarthritis in rats.
Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium.
Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized, Placebo-Controlled Study.
Down-regulation of cathepsin K in synovium leads to progression of osteoarthritis in rabbits.
Effects of cysteine proteases on the structural and mechanical properties of collagen fibers.
Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis.
Expression of bone resorption genes in osteoarthritis and in osteoporosis.
Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets.
Hyaluronan suppresses enhanced cathepsin K expression via activation of NF-?B with mechanical stress loading in a human chondrocytic HCS-2/8 cells.
Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage.
Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis.
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis.
Role of cathepsin K in normal joints and in the development of arthritis.
The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K.
The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.
The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis.
Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis.
Osteoarthritis, Knee
Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA.
Osteochondrodysplasias
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.
The genetic basis of the osteochondrodysplasias.
Osteolysis
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Blockade of NF-?B and MAPK Pathways by Ulinastatin Attenuates Particles-Stimulated Osteoclastogenesis in Vitro and in Vivo.
Cathepsin K inhibitors as treatment of bone metastasis.
Cathepsin K is the principal protease in giant cell tumor of bone.
Large osteocyte lacunae in iliac crest infantile bone are not associated with impaired mineral distribution or signs of osteocytic osteolysis.
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption.
Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence.
Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways.
Osteomyelitis
RANKL and cathepsin K in diffuse sclerosing osteomyelitis of the mandible.
Osteopetrosis
Cathepsin K and the design of inhibitors of cathepsin K.
Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization.
Clinical disorders of bone resorption.
Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.
Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family.
Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence.
Odontoblast-like MDPC-23 cells function as odontoclasts with the RANKL/M-CSF induction.
Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.
The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
The role of cathepsin K in normal bone resorption.
[A benign form of osteopetrosis. Case report]
Osteophyte
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.
The relative importance of cysteine peptidases in osteoarthritis.
Osteoporosis
3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K.
A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis.
A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods.
A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
Advances in the discovery of cathepsin K inhibitors on bone resorption.
An allosteric site enables fine-tuning of cathepsin K by diverse effectors.
An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature.
An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Articular cartilage protection in Ctsk-/- mice is associated with cellular and molecular changes in subchondral bone and cartilage matrix.
Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.
Bone metabolism in 2012: Novel osteoporosis targets.
Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy.
Carbon-11 labeled cathepsin K inhibitors: Syntheses and preliminary in vivo evaluation.
Cathepsin cysteine proteases in cardiovascular disease.
Cathepsin K and the design of inhibitors of cathepsin K.
Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.
Cathepsin K Deficiency Suppresses Disuse-Induced Bone Loss.
Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Cathepsin K inhibitor causes changes in crystallinity and crystal structure of newly-formed mandibular bone in rats.
Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
Cathepsin K inhibitors as treatment of bone metastasis.
Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.
Cathepsin K Inhibitors: A Novel Target but Promising Approach in the Treatment of Osteoporosis.
Cathepsin K inhibitors: a novel target for osteoporosis therapy.
Cathepsin K inhibitors: emerging treatment options for osteoporosis.
Cathepsin K Localizes to Equine Bone
Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
Cathepsin K, osteoclastic resorption, and osteoporosis therapy.
Cathepsin K: a unique collagenolytic cysteine peptidase.
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.
Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu Maxim.
Congress Report: 5th Central and Eastern Europe (CEE) Summit on Osteoporosis in Bratislava, 2-3 December 2011.
Cyclic ketone inhibitors of the cysteine protease cathepsin K.
Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation.
Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
Design of cathepsin k inhibitors for osteoporosis.
Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Detection of femtomole quantities of mature cathepsin K with zymography.
Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis.
Disposition and metabolism of the cathepsin k inhibitor odanacatib in humans.
Drug-induced morphea: report of a case induced by balicatib and review of the literature.
Drynaria total flavonoids decrease cathepsin K expression in ovariectomized rats.
Effect of cathepsin k inhibitor basicity on in vivo off-target activities.
Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: A head-to-head comparison with alendronate.
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies.
Effects of cysteine proteases on the structural and mechanical properties of collagen fibers.
Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5-year Data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Efficacy of calcium supplementation for human bone health by mass spectrometry profiling and cathepsin K measurement in plasma samples.
Efficiency of turnip bioactive lipids in treating osteoporosis through activation of Osterix and suppression of Cathepsin K and TNF-? signaling in rats.
Emerging roles of cysteine cathepsins in disease and their potential as drug targets.
Formulation of self-microemulsifying drug delivery system (SMEDDS) by D-optimal mixture design to enhance the oral bioavailability of a new cathepsin K inhibitor (HL235).
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.
Future Developments in Osteoporosis Therapy.
Future directions in osteoporosis therapeutics.
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Gumi Bao decoction regulates bone metabolism-related mRNA expression in glucocorticoid-induced osteoporosis in rats.
Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Inhibition of cathepsin k for treatment of osteoporosis.
Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats.
Inhibition of Cathepsin K: A Novel and Promising Treatment for Osteoporosis.
Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An In Silico and In Vitro Study.
Inhibitors of cathepsin K: a patent review (2004 - 2010).
Interventional value of total flavonoids from Rhizoma Drynariae on Cathepsin K, a potential target of osteoporosis.
Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
Laboratory control of the osteoresorptive effects of glucorcorticoids in patients with purpose colitis.
Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice.
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib.
Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor ?B ligand in the diagnosis of osteoporosis.
New antiresorptive therapies for postmenopausal osteoporosis.
New horizons in treatment of osteoporosis.
Non-covalent cathepsin k inhibitors for the treatment of osteoporosis.
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Novel advances in the treatment of osteoporosis.
Odanacatib for the treatment of osteoporosis.
Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women.
Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys.
Odanacatib, a Cathepsin K Cysteine Protease Inhibitor, Kills Hookworm In Vivo.
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density.
Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.
Odanacatib, a Selective Cathepsin K inhibitor to Treat Osteoporosis: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics - Results from Single Oral Dose Studies in Healthy Volunteers.
Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.
Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Osteopenia due to enhanced cathepsin K release by BK channel ablation in osteoclasts.
Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton.
Osteoporosis: A Review of Treatment Options.
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Peptidomimetic inhibitors of cathepsin K.
Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO-5334, in an Ascending Multiple-Dose, Phase 1 Study.
Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.
Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides.
Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Potential role of odanacatib in the treatment of osteoporosis.
Preclinical evaluation of [11 C]L-235 as a radioligand for Positron Emission Tomography cathepsin K imaging in bone.
Preparation of active recombinant cathepsin K expressed in bacteria as inclusion body.
Probing the activity modification space of the cysteine peptidase cathepsin K with novel allosteric modifiers.
Protective effect of resveratrol on estrogen deficiency-induced osteoporosis though attenuating NADPH oxidase 4/nuclear factor kappa B pathway by increasing miR-92b-3p expression.
Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice.
Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Serum Cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.
Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?
Structural basis of collagen fiber degradation by cathepsin K.
Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor.
Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
The development and characterization of an ELISA specifically detecting the active form of cathepsin K.
The effect of cathepsin K deficiency on airway development and TGF-?1 degradation.
The future of osteoporosis treatment - a research update.
The new partnership of genomics and chemistry for accelerated drug development.
The preventive effect of Cuscutae Semen polysaccharide on bone loss in the ovariectomized rat model.
The role of cathepsin K in normal bone resorption.
The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
[Cathepsin K and matrix metalloproteases activity in the bone tissue of OXYS rats with developing osteoporosis].
[New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334].
[Odanacatib (MK-0822)].
[Osteoporosis]
[Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
[Up-and-coming therapeutics for osteoporosis].
Osteoporosis, Postmenopausal
Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis.
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo.
Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture and Estimated Bone Strength.
New targets for intervention in the treatment of postmenopausal osteoporosis.
Odanacatib for the treatment of postmenopausal osteoporosis.
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.
Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Safety and efficacy of the Cathepsin K inhibitor, ONO-5334, in postmenopausal osteoporosis - the OCEAN study.
Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients.
The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: The OCEAN study.
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Treatment of postmenopausal osteoporosis with odanacatib.
Osteoradionecrosis
Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis-a paradoxical observation?
Osteosarcoma
An Activity-Based Probe for Cathepsin K Imaging with Excellent Potency and Selectivity.
Cathepsin K expression and activity in canine osteosarcoma.
Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis.
Cysteine proteinases in chondrosarcomas.
Osteosclerosis
Ablation of cathepsin k activity in the young mouse causes hypermineralization of long bone and growth plates.
Current research on pycnodysostosis.
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.
Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis.
Orthognathic surgery in pycnodysostosis: a case report.
The role of cathepsin K in normal bone resorption.
Use of CBCT in the orthodontic diagnosis of a patient with pycnodysostosis.
Paget Disease, Extramammary
Overexpression of stromal cathepsin K expression correlates with invasiveness of extramammary Paget's disease.
Papilledema
Multisuture Craniosynostosis and Papilledema in Pycnodysostosis: A Paradox?
Paraganglioma
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Peri-Implantitis
Cathepsin K levels in the crevicular fluid of dental implants: a pilot study.
Estimation of Bone Loss Biomarkers as a Diagnostic Tool for Peri-Implantitis.
Microbiological Profile and Human Immune Response Associated with Peri-Implantitis: A Systematic Review.
[Diagnostic possibilities of laboratory assessment of cathepsin K activity in gingival and peri-implant fluid under normal conditions and periimplantitis].
[Osteoimmunological aspects of periodontal inflammatory destructive changes at periimplantitis, chronic periodontitis and oncological diseases of the oral cavity].
Periapical Diseases
A small molecule, Odanacatib, inhibits inflammation and bone loss caused by endodontic disease.
Periapical Granuloma
Participation of osteoclastogenic factors in immunopathogenesis of human chronic periapical lesions.
Periapical Periodontitis
Ovariectomy Exacerbates Apical Periodontitis in Rats with an Increase in Expression of Proinflammatory Cytokines and Matrix Metalloproteinases.
Periodontal Diseases
Elevated Expression of Cathepsin K in Periodontal Ligament Fibroblast by Inflammatory Cytokines Accelerates Osteoclastogenesis via Paracrine Mechanism in Periodontal Disease.
Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis.
The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation.
Periodontal Pocket
[Osteoimmunological aspects of periodontal inflammatory destructive changes at periimplantitis, chronic periodontitis and oncological diseases of the oral cavity].
Periodontitis
Azilsartan increases levels of IL-10, down-regulates MMP-2, MMP-9, RANKL/RANK, Cathepsin K and up-regulates OPG in an experimental periodontitis model.
Cathepsin K Localizes to Equine Bone
Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role.
Effect of nonsurgical periodontal therapy on crevicular fluid levels of Cathepsin K in periodontitis.
Effects of Probiotic Culture Supernatant on Cariogenic Biofilm Formation and RANKL-Induced Osteoclastogenesis in RAW 264.7 Macrophages.
Expression of cathepsin K in periodontitis and in gingival fibroblasts.
Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis.
Inhibition of cathepsin K alleviates autophagy-related inflammation in periodontitis-aggravating arthritis.
Inhibition of Ctsk modulates periodontitis with arthritis via downregulation of TLR9 and autophagy.
Role of enhancer of zeste homolog 2 in osteoclast formation and periodontitis development by downregulating microRNA-101-regulated VCAM-1.
The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation.
Perivascular Epithelioid Cell Neoplasms
A distinctive subset of PEComas harbors TFE3 gene fusions.
Angiomyomatous Hamartoma of Lymph Nodes, Revisited: Clinico-pathologic Study of 21 Cases, Emphasizing Its Distinction from Lymphangioleiomyomatosis of Lymph Nodes.
Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas.
Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung.
Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis.
PEComas of the kidney and of the genitourinary tract.
PNL2: A Useful Adjunct Biomarker to HMB45 in the Diagnosis of Uterine Perivascular Epithelioid Cell Tumor (PEComa).
PNL2: An Adjunctive Biomarker for Renal Angiomyolipomas and PEComas.
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Persistent Infection
The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation.
Pituitary Neoplasms
Cathepsin K: The association between Cathepsin K expression and sphenoid sinus invasion of pituitary adenomas.
Prostatic Hyperplasia
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Prostatic Neoplasms
Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.
Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?
Cathepsin K mRNA and protein expression in prostate cancer progression.
Cathepsin K: The association between Cathepsin K expression and sphenoid sinus invasion of pituitary adenomas.
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Psoriasis
Effect of Vitamin D on Peripheral Blood Mononuclear Cells from Patients with Psoriasis Vulgaris and Psoriatic Arthritis.
Pulmonary Disease, Chronic Obstructive
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
Pulmonary Fibrosis
Cathepsin K expression is diminished in infants with bronchopulmonary dysplasia.
Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis.
Pycnodysostosis
A Case Report of Pycnodysostosis Associated with Multiple Pituitary Hormone Deficiencies and Response to Treatment
A case report of pycnodysostosis with atypical femur fracture diagnosed by next-generation sequencing of candidate genes.
A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis.
A novel missense mutation in cathepsin K (CTSK) gene in a consanguineous Pakistani family with pycnodysostosis.
A novel mutation (R122Q) in the cathepsin K gene in a Chinese child with Pyknodysostosis.
A patient with pycnodysostosis presenting with seizures and porencephalic cysts.
A rare case of pycnodysostosis: Technical difficulties in managing long bone fractures.
Ablation of cathepsin k activity in the young mouse causes hypermineralization of long bone and growth plates.
Alternative Method for Full Oral Rehabilitation in Patients with Pycnodysostosis Syndrome: ?A Case Report.
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling.
Articular cartilage protection in Ctsk-/- mice is associated with cellular and molecular changes in subchondral bone and cartilage matrix.
Atypical femur fractures in a patient with pycnodysostosis: a case report.
Bilateral subtrochanteric femoral fracture due to a very rare disease: Pycnodisostosis.
Cathepsin K analysis in a pycnodysostosis cohort: demographic, genotypic and phenotypic features.
Cathepsin K and the design of inhibitors of cathepsin K.
Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts.
Cathepsin K gene mutations and 1q21 haplotypes in at patients with pycnodysostosis in an outbred population.
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization.
Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
Cathepsin K: isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene.
Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis.
Characterization of the human extracellular matrix protein 1 gene on chromosome 1q21.
Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011.
Clinical and genetic evaluation of Danish patients with pycnodysostosis.
Clinical and Radiographic Features of Pycnodysostosis with Emphasis on Dentofacial Problems.
Clinical disorders of bone resorption.
Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.
Craniosynostosis in pycnodysostosis: broadening the spectrum of the cranial flat bone abnormalities.
Current research on pycnodysostosis.
Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis.
Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.
Disturbed remodeling and delayed fracture healing in pediatric pycnodysostosis patients.
Effects of cathepsin K on Emdogain-induced hard tissue formation by human periodontal ligament stem cells.
Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.
Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice.
Genetic study of eight Egyptian patients with pycnodysostosis: identification of novel CTSK mutations and founder effect.
Human osteopetrosis and other sclerosing disorders: recent genetic developments.
Ichthyosis vulgaris and pycnodysostosis: an unusual occurrence.
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.
Increased Bone Resorption during Lactation in Pycnodysostosis.
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family.
Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis.
Molecular analysis of a novel cathepsin K gene mutation in a Chinese child with pycnodysostosis.
Molecular and clinical analysis in a series of patients with Pyknodysostosis reveals some uncommon phenotypic findings.
Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia.
Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein.
Near Normalization of Adult Height and Body Proportions by Growth Hormone in Pycnodysostosis.
Novel Compound Heterozygous Mutations in the Cathepsin K Gene in Japanese Female Siblings with Pyknodysostosis.
Novel Mutation and White Matter Involvement in an Indian Child with Pycnodysostosis.
Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization.
Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence.
Orthognathic surgery in pycnodysostosis: a case report.
Osteopetrosis and osteoporosis: two sides of the same coin.
Pedicle stress fracture: an unusual complication of pycnodysostosis.
Pycnodysostosis at otorhinolaryngology.
Pycnodysostosis presenting as atypical stridor.
Pycnodysostosis with extreme sleep apnea: a possible alternative to tracheotomy.
Pycnodysostosis with novel gene mutation and sporadic medullary thyroid carcinoma: A case report.
Pycnodysostosis with Osteomyelitis of Maxilla: Case Report of Radiological Analysis.
Pycnodysostosis with unusual findings: a case report.
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
Pycnodysostosis: Novel Variants in
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
Pyknodysostosis: visceral manifestations and simian crease.
Recent advances in osteoclast biology and pathological bone resorption.
Structure and chromosomal assignment of the human cathepsin K gene.
The role of cathepsin K in normal bone resorption.
Upper airway surgery of obstructive sleep apnea in pycnodysostosis: Case report and literature review.
Use of CBCT in the orthodontic diagnosis of a patient with pycnodysostosis.
[Family picnodisostosis, report of a case after 10 years of follow-up].
[Pycnodysostosis--common ancestor of some Danish patients. Examination and diagnosis based on molecular genetics]
[Pycnodysostosis: A rare disease with frequent fractures.]
Radicular Cyst
Participation of osteoclastogenic factors in immunopathogenesis of human chronic periapical lesions.
Renal Insufficiency, Chronic
Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.
Novel biological markers of bone: from bone metabolism to bone physiology.
Rheumatic Diseases
Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton.
Root Resorption
Chemerin/ChemR23 regulates cementoblast function and tooth resorption in mice via inflammatory factors.
Comparison of expression patterns of cathepsin K and MMP-9 in odontoclasts and osteoclasts in physiological root resorption in the rat molar.
Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
Immunolocalization of vacuolar-type H+-ATPase, cathepsin K, matrix metalloproteinase-9, and receptor activator of NFkappaB ligand in odontoclasts during physiological root resorption of human deciduous teeth.
In situ hybridization for matrix metalloproteinase-1 and cathepsin K in rat root-resorbing tissue induced by tooth movement.
Localization of cathepsin K in bovine odontoclasts during deciduous tooth resorption.
The effect of cathepsin K inhibitor surface treatment on delayed tooth replantation in dogs.
[Expression of cathepsin K and IL-6 mRNA in root-resorbing tissue during tooth movement in rats]
Sacroiliitis
Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis.
Sarcoidosis
ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.
Lack of cathepsin activities alter or prevent the development of lung granulomas in a mouse model of sarcoidosis.
Sarcoma
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Sarcoma, Alveolar Soft Part
A broad survey of cathepsin K immunoreactivity in human neoplasms.
Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Scleroderma, Localized
Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation.
Spondylitis, Ankylosing
Expression of cathepsin K and MMP-1 indicate persistent osteodestruktive activity in longstanding ankylosing spondylitis.
Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
The development and characterization of an ELISA specifically detecting the active form of cathepsin K.
Squamous Cell Carcinoma of Head and Neck
Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma.
Cathepsin k is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro.
Cathepsin K modulates invasion, migration and adhesion of oral squamous cell carcinomas in vitro.
Stomach Neoplasms
Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K.
Stuttering
Communication Attitude of Kannada-Speaking School-Age Children Who Do and Do Not Stutter.
Synovitis
Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K.
Tendinopathy
Involvement of multinucleated giant cells synthesizing cathepsin K in calcified tendinitis of the rotator cuff tendons.
Sequential, but not Concurrent, Incubation of Cathepsin K and L with Type I Collagen Results in Extended Proteolysis.
Thrombosis
Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation.
Thyroid Neoplasms
High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy.
Tooth Resorption
Localization of cathepsin K in bovine odontoclasts during deciduous tooth resorption.
Tuberculosis, Pulmonary
Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.
Vascular Calcification
Cathepsin-K is a potential cardiovascular risk biomarker in prevalent hemodialysis patients.
Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.
Novel biological markers of bone: from bone metabolism to bone physiology.
Vascular Diseases
Circulating cathepsin K as a potential novel biomarker of coronary artery disease.